- Home
- Companies
- north america
- cancer drive gene mutations detection
Show results for
Refine by
Cancer Drive Gene Mutations Detection Suppliers In North America
33 companies found
based inNottingham, UNITED KINGDOM
Oncimmune is a leading immuno diagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Our growing range of diagnostic products can detect early-stage cancer and our service-based ...
EarlyCDT is a simple blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defence against cancer cells. EarlyCDT Lung is the world’s most thoroughly validated blood test for the ...
based inSeville, SPAIN
We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable. We are developing Signal-X™, a multi-cancer platform able to detect various types of high-burden ...
We are developing Signal-X, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. ...
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique ...
based inLa Jolla, CALIFORNIA (USA)
Avelas is a clinical-stage drug-device company pioneering the field of fluorescence imaging for real-time cancer detection. Avelas is focused on the development and commercialization of pegloprastide (also referred to as “AVB-620”), a novel ...
Pegloprastide (AVB-620) is based on the science of activatable cell-penetrating peptides and is designed to deliver a fluorescent marker specifically to cancer cells to enable surgeons to identify cancerous tissue in real-time and thus, avoid repeat ...
based inMenlo Park, CALIFORNIA (USA)
We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power ...
GRAIL is poised to detect cancer early by combining high-intensity sequencing of unprecedented breadth and depth with the techniques of modern data science. Through what we believe to be one of the largest clinical study programs ever pursued in ...
based inLos Altos, CALIFORNIA (USA)
QView Medical, Inc. is a Silicon Valley based private company. The QView team has been the leader in CAD and ABUS development. For over 20 years, members of the team have been involved in obtaining four PMA approvals: R2 mammography CAD, R2 lung CT ...
based inLund, SWEDEN
Our mission is to make it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genetics and proteomics. We do this by providing powerful visualization-based bioinformatics data analysis tools for ...
based inGaithersburg, MARYLAND (USA)
20/20 GeneSystems Inc. develops and commercializes diagnostic tests for the early detection of cancer to improve outcomes of people at high risk for specific types of cancers. It offers blood tests for use in the United States to aid in the early ...
based inOrlando, FLORIDA (USA)
Imaging Diagnostic Systems, Inc. (IDSI) is a medical device company headquartered in Florida, specializing in the research, development, and marketing of innovative cancer detection systems. Their flagship product, the CTLM system (Computed ...
Computed Tomography Laser Mammography (CTLM) is an innovative imaging method focused on visualizing blood distribution within the breast, helpful for identifying breast abnormalities. This technology offers potential advantages in detecting ...
based inSugar Land, TEXAS (USA)
TransLite LLC is a small high tech company comprising dedicated people who design, manufacture and sell medical devices that can help reduce the pain and trauma to patients during venous access and treatment of varicose veins. Over 70,000 medical ...
based inPhoenix, ARIZONA (USA)
VisionGate, Inc., is a breakthrough liquid-biopsy technology company, leading the battle against lung cancer through early detection technology with a simple, non-intrusive sputum test. The foundation for our diagnostics capability is the ...
The LuCED test is a non-intrusive sputum sample that we collect from you and then analyze using our Cell-CT machine. From this sample, LuCED is designed to detect lung cancer early by detecting the abnormal cells. ...
based inNatick, MASSACHUSETTS (USA)
DYSIS Medical is a medical device company that designs, develops, manufactures and markets imaging systems focusing on the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. DYSIS Medical has developed a proprietary technology ...
based inBrisbane, CALIFORNIA (USA)
Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. ...
based in, CALIFORNIA (USA)
At Delee we’re fundamentally changing not only the way cancer is detected but also how it could be treated. By developing a device capable of capturing Circulating Tumor Cells (CTCs) in a faster and more effective way than the current technologies ...
based inNotting Hill, AUSTRALIA
INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases to improve patient outcomes ...
INOVIQ’s NETs technology is a sample preparation platform with the potential to revolutionise the performance of liquid biopsy diagnostic assays. The market potential for liquid biopsy applications is estimated at billions of dollars ...
based inSan Diego, CALIFORNIA (USA)
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses ...
Liquid biopsies are a new powerful tool in cancer diagnostics that is transforming patient healthcare. Body fluids such as blood or urine are obtained from the patient and analyzed for the presence of circulating tumor DNA which is shed from the ...
based inSykesville, MARYLAND (USA)
OTraces, Inc. has built, and extensively filed patents protection on, an early tumor detection and cancer screening software technology. Technology uses well-known math- and physics-based A-I methods including those used in advanced satellite ...
BC Sera Dx Immunoassay test panel for detection of the presence of breast cancer in women. In the development pipeline are an Ovarian, OV Sera Dx, and Lung, LG Sera Dx, cancer detection test ...
based inWest Vancouver, BRITISH COLUMBIA (CANADA)
Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. ...
based inWaterside, UNITED KINGDOM
Lightpoint Medical is a technology leader in targeted cancer surgery. We are developing miniaturized imaging and sensing tools for more precise intra-operative cancer detection. Our mission is to improve the lives of people with cancer by ...
Using next-generation miniaturized sensor technology, the SENSEI probe measures just over 40mm in length, enabling unprecedented intracavity maneuverability and anatomic access for surgical ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease ...
